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Tufts Medical Center 800 Washington Street, Boston, MA 02111, United StatesThere are few therapeutic ﬁelds in which the need for an
impartial, balanced, synthesis of the evidence is as great
as for osteoarthritis (OA). The disorder is one of the most
frequent and costly causes of physical disablement in the
population1, yet no especially effective intervention or ther-
apy has emerged. As a result, there is as astonishing range
of promulgated therapies, many of which are marketed
directly to consumers e often, apparently, in the face of
compelling scientiﬁc evidence of their inefﬁcacy2. Even
among experts, there are examples of a striking propensity
for differing interpretations of available data3e5. A robust
and respected evidence synthesis would clearly be of value
to assist health professionals and individuals with OA in
making wise treatment choices and optimizing resource
allocation.
Historically, the development of broadly acceptable treat-
ment guidelines for OA has been a challenge. As Zhang
et al. highlight in this most recent endeavor6, previous iter-
ations from different constituencies produced no universally
agreed recommendations, even for a core group of safe and
effective therapies. It is evident that the acceptability of
guidelines is almost entirely contingent on the perceived ro-
bustness of their methodological origin. The sophistication
of methodologies for achieving evidence-based consensus
has advanced considerably, but so has their complexity and
level of effort. Furthermore, the ﬁeld has exhibited shifting
paradigms and may not yet have solidiﬁed. For example,
consensus on the optimal methodology shifted from
opinion-based (with its potential for bias) to a more purist
evidence-based synthesis of high quality evidence (which
could be patchy and theoretical) to a more balanced hybrid
approach that aims to integrate research evidence with
clinical expertise. Though there are advantages to the
hybrid approach, there are also potential pitfalls including
potential for variability in its deployment. The 2003 EULAR
OA task force, for example, solicited propositions from the
expert panel as a ﬁrst step, and next sought evidence on
those propositions7. This may have constrained the scope
of therapies brought under consideration.
Thus, with a remit from OARSI, and evidently mindful of
the methodological milieu, Zhang and the guideline*Address correspondence and reprint requests to: Dr Tim
McAlindon, Division of Rheumatology, Tufts-New England
Medical Center, 800 Washington Street, Tufts Medical Center,
Box 406, Boston, MA 02111, United States. Tel: 1-617-636-5645;
Fax: 1-617-636-1542; E-mail: http://www.nemc.org/medicine/
rheumatology, tmcalindon@tufts-nemc.org
636development panel planned a more logical but burdensome
approach that reversed these steps e evidence-driven first
and clinically-supported second (6 and guideline Ref.10).
However, the enormity of the task inherent in the ﬁrst step
(appraisal of the totality of evidence on OA treatments)
seems to have obligated the OARSI panel to reduce their
burden by performing instead an appraisal of existing
2003 EULAR guidelines, updated by a systematic review
of subsequent evidence e itself not a trivial endeavor!
This seems like a reasonable reductionist step to enable
the feasibility of the global data synthesis but it might still
leave vulnerability to omission of data on treatments not
considered in prior guidelines. It might also make readers
wonder about the level of detail that informed the experts’
decisions. How, for example, would they weigh a ﬂawed
meta-analysis (viewed as the top level of evidence in the
hierarchy) against high quality clinical trial results (which
would have been omitted in the systematic review of recent
evidence)? What would they do with pooled effect size
estimates from high quality meta-analyses that doubted
their own results because of problems with the included
trials (a common situation apparently8,9)?
So what emerged on the formidable journey through
evidence gathering towards formulation of consensus?
Quite a few illuminating pieces of information, as it turns
out. Firstly, among the 23 guidelines that met inclusion
criteria for critical appraisal, there was considerable varia-
tion in setting (e.g., rheumatology vs orthopedics) and
also in what treatments were considered. There were signif-
icant differences in mean quality scores between guidelines
subsets with opinion-based formulations scoring lowest.
Among 51 treatment modalities collectively addressed, 20
were recommended by all, but the denominator varied
(e.g., treatment with ‘herbs’ was addressed in only two
guideline sets but recommended by both e ‘100% consen-
sus’!). Somewhat paradoxically, the strength of consensus
for a treatment did not necessarily reﬂect the level of
evidence in any of the guideline sets (including this one).
For example, ultrasound therapy received weak support,
notwithstanding positive results in clinical trials, yet there
was strong support for surgical procedures, which were
supported only by uncontrolled or observational data.
Clearly, a great number of unmeasured factors inﬂuence
the decision to recommend.
The guideline development process also rests on the
capacity of the expert panel to accurately synthesize the
presented information and reach consensus. It is gratifying
that the panel here was reasonably representative of
637Osteoarthritis and Cartilage Vol. 16, No. 6experts in pertinent disciplines, of Europe and North
America, and provided illuminating information on Industry
afﬁliations. Importantly, panelists that perceived themselves
to have potential conﬂict of interest were able to (and did)
recuse themselves from voting on individual propositions.
The Delphi process consisted of developing and reﬁning
a series of data-based propositions among the panel until
a level of consensus was reached. In fact, the exercise
appears to have been so effective in crafting carefully-
worded text that, at times, its melliﬂuence seems primarily
intended to avoid contention rather than provide speciﬁc
directive. Nevertheless, the propositions are generally
down-to-earth statements about commonly-used modalities
about which some consensus will have great utility.
The most appealing output of this analysis, however,
lies in the aim to quantify level and strength of consensus
achieved for each proposition. This information should
enable us to weigh, or rank, the level of conviction held
by the panel for each recommendation. In accepting
that treatment issues are rarely dichotomous, this
approaches the additional advantage of removing the
overly directive tone of many guidelines. However, there
is some complexity in interpretation of their metrics. For
example, the visual analog scale used to measure
strength of recommendation does not have clearly
deﬁned anchor points for the extremes. So, it was unclear
to me whether ‘0’ represents equipoise or a view that the
evidence suggests that the modality does not work. The
ﬁrst situation would present the possibility of bias due to
a ﬂoor effect, while the second would push equipoise
into the middle of the VAS and hinder interpretation of
the numeric value. It also proved difﬁcult at times to
reconcile the scores for level and strength of consensus.
What does it mean, for example, that the proposition for
acetaminophen (a pharmaceutical recommended in
100% of prior guidelines) received only 77% consensus
yet a 92% strength of recommendation? Or, in contrast,
that the proposition for joint lavage/arthroscopic debride-
ment has consensus of 100% yet a strength of recom-
mendation of 60%? Scrutiny of the phrasing of the
proposition, or the detailed proposition in the manuscript,
does provide clariﬁcation in many cases, since votes for
strength of recommendation were for the propositions
along with included caveats. Until we grow more familiar
with the external benchmarks of these two parameters,
it may be prudent to view them as ranking metrics for
(1) the proposition as stated, and (2) the level of convic-
tion of the usefulness of that modality in a clinical setting.
So how do the OARSI recommendations perform in a test
run? I was jarred only by proposition 1, an articulation of OA
folklore that does not contain a scientiﬁcally-testablehypothesis, appears to be based entirely on opinion, yet
received among the highest strengths of recommendation.
Propositions for controversial treatments (e.g., glucosamine
and hyaluronate) or interventions with limited or negative
data (e.g., joint lavage) were present but ranked appropri-
ately low for strengths of recommendation. What did
emerge was the omission of some prominent studies that
were published subsequent to the Delphi exercise. This
was probably unavoidable and, according to the sensitivity
analysis, non-inﬂuential. However, this remains a more
general dilemma if, as the authors assert, a consequence
of their burden and complexity is that guideline develop-
ment in fast-moving ﬁelds will never be quite current. Could
this whole exercise be reconﬁgured to facilitate frequent
updates, or even real-time adjustments, perhaps leveraging
the power of the Internet? We should challenge the OARSI
guidelines panel, at the completion of this considerable
endeavor, to apply their evident creativity in the accomplish-
ment of such an ideal.References
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